Tumor mutation burden (TMB) is an emerging biomarker that is rapidly gaining traction within the immuno-oncology field. Recent clinical trials have demonstrated that patients with higher TMB are more likely to respond to check point inhibitor therapies, so it will likely become a part of routine clinical biomarker testing in the near future. Studies have shown that NGS is the best technique for detecting TMB. The Oncomine Tumor Mutation Load Assay is the only NGS solution available for use in clinical research laboratories that delivers a TMB assessment in one test workflow with other biomarkers.
See short videos of key opinion leaders talking about their experience with the test and assessing tumor mutation burden in ~2.5 days.
Molecular analysis of hematological malignancies usually involves a complex, single-gene targeted molecular triage protocol, which can suffer from limitations. NGS technology consolidates and simplifies this protocol, enabling a common method for all specimens, decreased turnaround time, and potentially higher diagnostic yield. The Ion Torrent Oncomine Myeloid Research Assay provides:
• Comprehensive coverage of single nucleotide variants (SNVs), indels, gene fusions, drivers, and expression
• Simple and automated two- or three-day workflow depending on sample
• Streamlined end-to-end informatics solution, including a report and interpretation of results
Watch a video of Dr. Bekim Sadikovic from Canada share how NGS can consolidate molecular testing of myeloid samples.
Whether you’re looking at multiple targets or just a few, our NGS solutions combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages.
For Research Use Only. Not for use in diagnostic procedures.